Anti-inflammatory agents suppress the prostaglandin e2 production and migration ability of Cholangiocarcinoma cell lines

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue SUPPL.1, 2012, Pages 47-51

  Jongthawin, Jurairat ^a   Techasen, Anchalee ^a   Loilome, Watcharin ^a   Yongvanit, Puangrat ^a   Namwat, Nisana ^a  

^a KHON KAEN UNIVERSITY   (Thailand)

Author keywords

Cholangiocarcinoma; Meloxicam; Xanthohumol

Indexed keywords

CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; PROSTAGLANDIN E2;

BILE DUCT CARCINOMA; BILE DUCT TUMOR; CELL MOTION; CELL PROLIFERATION; DRUG EFFECTS; HUMAN; INTRAHEPATIC BILE DUCT; METABOLISM;

BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CELL MOVEMENT; CELL PROLIFERATION; CHOLANGIOCARCINOMA; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; HUMANS;

EID: 84874060544     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.KKSuppl.47     Document Type: Article

References (39)

1. Boonjaraspinyo S, Wu Z, Boonmars T, et al (2011). Overexpression of PDGFA and its receptor during carcinogenesis of Opisthorchis viverrini-associated cholangiocarcinoma. Parasitol Int, 61, 145-50.
2. Chariyalertsak S, Sirikulchayanonta V, Mayer D, et al (2001). Aberrant cyclooxygenase isozyme expression in human intrahepatic cholangiocarcinoma. Gut, 48, 80-6.
3. Engelhardt G, Homma D, Schlegel K, et al (1995). Antiinflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance. Inflamm Res, 44, 423-33.
4. Gerhauser C (2005). Beer constituents as potential cancer chemopreventive agents. Eur J Cancer, 41, 1941-54.
5. Gerhauser C, Alt A, Heiss E, et al (2002). Cancer chemopreventive activity of xanthohumol, a natural product derived from hop. Mol Cancer Ther, 1, 959-69.
6. Goldman A P, Williams C S, Sheng H, et al (1998). Meloxicam inhibits the growth of colorectal cancer cells. Carcinogenesis, 19, 2195-9.
7. Goto K, Asai T, Hara S, et al (2005). Enhanced antitumor activity of xanthohumol, a diacylglycerol acyltransferase inhibitor, under hypoxia. Cancer Lett, 219, 215-22.
8. Gupta G P, Nguyen D X, Chiang A C, et al (2007). Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature, 446, 765-70.
9. 2 (PGE)2/EP1 and peroxisome proliferator-activated receptor-gamma (PPAR-gamma)/Smad signaling pathways in human liver cancer cells. A novel mechanism for subversion of TGFbeta-induced mitoinhibition. J Biol Chem, 279, 44344-54.
10. Han C, Wu T (2005). Cyclooxygenase-2-derived prostaglandin E2 promotes human cholangiocarcinoma cell growth and invasion through EP1 receptor-mediated activation of the epidermal growth factor receptor and Akt. J Biol Chem, 280, 24053-63.
11. Heinonen P K and Metsa-Ketela T (1984). Prostaglandin and thromboxane production in ovarian cancer tissue. Gynecol Obstet Invest, 18, 225-9.
12. Itatsu K, Sasaki M, Yamaguchi J, et al (2009). Cyclooxygenase-2 is involved in the up-regulation of matrix metalloproteinase-9 in cholangiocarcinoma induced by tumor necrosis factoralpha. Am J Pathol, 174, 829-41.
13. Jacobs E J, Thun M J, Bain E B, et al (2007). A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst, 99, 608-15.
14. Lai G H, Zhang Z, Sirica A E (2003). Celecoxib acts in a cyclooxygenase-2-independent manner and in synergy with emodin to suppress rat cholangiocarcinoma growth in vitro through a mechanism involving enhanced Akt inactivation and increased activation of caspases-9 and -3. Mol Cancer Ther, 2, 265-71.
15. Lampugnani M G (1999). Cell migration into a wounded area in vitro. Methods Mol Biol, 96, 177-82.
16. Li J, Chen X, Dong X, et al (2006). Specific COX-2 inhibitor, meloxicam, suppresses proliferation and induces apoptosis in human HepG2 hepatocellular carcinoma cells. J Gastroenterol Hepatol, 21, 1814-20.
17. Liu X H, Kirschenbaum A, Lu M, et al (2002). Prostaglandin E(2) stimulates prostatic intraepithelial neoplasia cell growth through activation of the interleukin-6/GP130/STAT-3 signaling pathway. Biochem Biophys Res Commun, 290, 249-55.
18. Loilome W, Wechagama P, Namwat N, et al (2011). Expression of oxysterol binding protein isoforms in opisthorchiasisassociated cholangiocarcinoma: a potential molecular marker for tumor metastasis. Parasitol Int, 61, 136-9.
19. Lust S, Vanhoecke B, Janssens A, et al (2005). Xanthohumol kills B-chronic lymphocytic leukemia cells by an apoptotic mechanism. Mol Nutr Food Res, 49, 844-50.
20. Miranda C L, Yang Y H, Henderson M C, et al (2000). Prenylflavonoids from hops inhibit the metabolic activation of the carcinogenic heterocyclic amine 2-amino-3-methylimidazo[4,5-f]quinoline, mediated by cDNAexpressed human CYP1A2. Drug Metab Dispos, 28, 1297-302.
21. Miyaura C, Inada M, Matsumoto C, et al (2003). An essential role of cytosolic phospholipase A2alpha in prostaglandin E2-mediated bone resorption associated with inflammation. J Exp Med, 197, 1303-10.
22. Montejo C, Barcia E, Negro S & Fernandez-Carballido A (2010). Effective antiproliferative effect of meloxicam on prostate cancer cells: development of a new controlled release system. Int J Pharm, 387, 223-9.
23. Namwat N, Amimanan P, Loilome W, et al (2008). Characterization of 5-fluorouracil-resistant cholangiocarcinoma cell lines. Chemotherapy, 54, 343-51.
24. Namwat N, Puetkasichonpasutha J, Loilome W, et al (2011). Downregulation of reversion-inducing-cysteine-rich protein with Kazal motifs (RECK) is associated with enhanced expression of matrix metalloproteinases and cholangiocarcinoma metastases. J Gastroenterol, 46, 664-75.
25. Naruse T, Nishida Y, Hosono K & Ishiguro N (2006). Meloxicam inhibits osteosarcoma growth, invasiveness and metastasis by COX-2-dependent and independent routes. Carcinogenesis, 27, 584-92.
26. Noble S and Balfour J A (1996). Meloxicam. Drugs, 51, 424-30.
27. Ogino K, Hatanaka K, Kawamura M, et al (1997). Evaluation of pharmacological profile of meloxicam as an antiinflammatory agent, with particular reference to its relative selectivity for cyclooxygenase-2 over cyclooxygenase-1. Pharmacology, 55, 44-53.
28. Qualtrough D, Kaidi A, Chell S, et al (2007). Prostaglandin F(2alpha) stimulates motility and invasion in colorectal tumor cells. Int J Cancer, 121, 734-40.
29. Skehan P, Storeng R, Scudiero D, et al (1990). New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst, 82, 1107-12.
30. Stevens J F and Page J E (2004). Xanthohumol and related prenylflavonoids from hops and beer: to your good health! Phytochemistry, 65, 1317-30.
31. Techasen A, Loilome W, Namwat N, et al (2010). Myristoylated alanine-rich C kinase substrate phosphorylation promotes cholangiocarcinoma cell migration and metastasis via the protein kinase C-dependent pathway. Cancer Sci, 101, 658-65.
32. Tsubouchi Y, Mukai S, Kawahito Y, et al (2000). Meloxicam inhibits the growth of non-small cell lung cancer. Anticancer Res, 20, 2867-72.
33. Tsuchida A, Itoi T, Kasuya K, et al (2005). Inhibitory effect of meloxicam, a cyclooxygenase-2 inhibitor, on N-nitrosobis (2-oxopropyl) amine induced biliary carcinogenesis in Syrian hamsters. Carcinogenesis, 26, 1922-8.
34. Vanhoecke B, Derycke L, Van Marck V, et al (2005). Antiinvasive effect of xanthohumol, a prenylated chalcone present in hops (Humulus lupulus L.) and beer. Int J Cancer, 117, 889-95.
35. Wu T (2005). Cyclooxygenase-2 and prostaglandin signaling in cholangiocarcinoma. Biochim Biophys Acta, 1755, 135-50.
36. Xin B, Yokoyama Y, Shigeto T, et al (2007). Inhibitory effect of meloxicam, a selective cyclooxygenase-2 inhibitor, and ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, on the growth of human ovarian cancers. Cancer, 110, 791-800.
37. Yoon J H, Higuchi H, Werneburg N W, et al (2002). Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line. Gastroenterology, 122, 985-93.
38. Zhang Z, Lai G H & Sirica A E (2004). Celecoxib-induced apoptosis in rat cholangiocarcinoma cells mediated by Akt inactivation and Bax translocation. Hepatology, 39, 1028-37.
39. Zhao F, Nozawa H, Daikonnya A, et al (2003). Inhibitors of nitric oxide production from hops (Humulus lupulus L.). Biol Pharm Bull, 26, 61-5.